You are here:Home-Chemical Inhibitors & Agonists-Ras-Raf-MAPK-ERK Pathway-MEK (MAP2K)-KZ-001
KZ-001

Chemical Structure : KZ-001

CAS No.: 1448441-53-9

KZ-001 (KZ001)

Catalog No.: PC-38901Not For Human Use, Lab Use Only.

KZ-001 is a highly potent and selective MEK 1/2 inhibitor with IC50 values of 7.4/64 nM, respectively, exhibits greater inhibition against BRAF- and KRAS-mutant tumor cells than AZD6244.

Packing Price Stock Quantity
25 mg Get quote
50 mg Get quote
100 mg Get quote
250 mg Get quote

Bulk size, bulk discount!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

Purity & Documentation Purity: >98% (HPLC) Select Batch:

    Biological Activity

    KZ-001 is a highly potent and selective MEK1/2 inhibitor with IC50 values of 7.4/64 nM, respectively, exhibits greater inhibition against BRAF- and KRAS-mutant tumor cells than AZD6244.
    KZ-001 has approximately 27-fold stronger activity than AZD6244.
    KZ-001 (1 nM to 625 nM) inhibits cellular ERK phosphorylation in A375, Calu-6, Colo-205 and HT-29 cells.
    KZ-001 shows much more potent inhibition of proliferation, with an IC50 of 2.9-5.7 nM and 169.9 nM for the BRAFV600E and KRASQ61K cancer cell lines, compare with AZD6244, the RAFWT and RASWT cell lines A431 are resistant to KZ-001.
    KZ-001 induces apoptosis in Colo-205 and Calu-6 cells, but not RAFWT and RASWT cell lines. KZ-001 (3 mg/kg and 6 mg/kg) completely inhibits the growth of Colo-205 tumors (TGI 103.9% and 108.8%, respectively; p < 0.01).
    KZ-001 shows synergistic effect against BRAF mutant cell lines in vitro and in vivo, when combined with vemurafenib and docetaxel.

    Physicochemical Properties

    M.Wt 475.190
    Formula C16H12F2IN3O4
    Appearance Solid
    CAS No.
    Storage
    Solide Powder
    -20°C 12 Months; 4°C 6 Months
    In Solvent
    -80°C 6 Months; -20°C 6 Months
    Shipping
    Solubility

    10 mM in DMSO

    Chemical Name/SMILES

    4-fluoro-5-((2-fluoro-4-iodophenyl)amino)-N-(2-hydroxyethoxy)benzo[d]oxazole-6-carboxamide

    References

    1. Ying Cheng, et al. Int J Cancer. 2019 Jul 15;145(2):586-596.

    Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright

    Contact Us sales@probechem.com

    Bulk Inquiry

    * Indicates a Required FieldYour information is safe with us.

    • *Product name:
    • *Applicant name:
    • *Email address:
    • *Organization name:
    • *Requested quantity:
    • *Country:
    • *Additional Information:

    Get Quote

    * Indicates a Required FieldYour information is safe with us.

    • *Product name:
    • *Applicant name:
    • *Email address:
    • *Organization name:
    • *Requested quantity:
    • *Country:
    • Additional Information: